American Association for Cancer Research
ccr-22-2784_supplementary_table_s3_suppts3.docx (18.77 kB)

Supplementary Table S3 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study

Download (18.77 kB)
journal contribution
posted on 2023-04-01, 00:23 authored by Zhiyuan Bo, Bo Chen, Zhengxiao Zhao, Qikuan He, Yicheng Mao, Yunjun Yang, Fei Yao, Yi Yang, Ziyan Chen, Jinhuan Yang, Haitao Yu, Jun Ma, Lijun Wu, Kaiyu Chen, Luhui Wang, Mingxun Wang, Zhehao Shi, Xinfei Yao, Yulong Dong, Xintong Shi, Yunfeng Shan, Zhengping Yu, Yi Wang, Gang Chen

Baseline characteristics between patients with unresectable HCC treated with lenvatinib in the training and external validation cohort.



We aimed to construct machine learning (ML) radiomics models to predict response to lenvatinib monotherapy for unresectable hepatocellular carcinoma (HCC). Patients with HCC receiving lenvatinib monotherapy at three institutions were retrospectively identified and assigned to training and external validation cohorts. Tumor response after initiation of lenvatinib was evaluated. Radiomics features were extracted from contrast-enhanced CT images. The K-means clustering algorithm was used to distinguish radiomics-based subtypes. Ten ML radiomics models were constructed and internally validated by 10-fold cross-validation. These models were subsequently verified in an external validation cohort. A total of 109 patients were identified for analysis, namely, 74 in the training cohort and 35 in the external validation cohort. Thirty-two patients showed partial response, 33 showed stable disease, and 44 showed progressive disease. The overall response rate (ORR) was 29.4%, and the disease control rate was 59.6%. A total of 224 radiomics features were extracted, and 25 significant features were identified for further analysis. Two distant radiomics-based subtypes were identified by K-means clustering, and subtype 1 was associated with a higher ORR and longer progression-free survival (PFS). Among the 10 ML algorithms, AutoGluon displayed the highest predictive performance (AUC = 0.97), which was relatively stable in the validation cohort (AUC = 0.93). Kaplan–Meier analysis showed that responders had a better overall survival [HR = 0.21; 95% confidence interval (CI): 0.12–0.36; P < 0.001] and PFS (HR = 0.14; 95% CI: 0.09–0.22; P < 0.001) than nonresponders. Valuable ML radiomics models were constructed, with favorable performance in predicting the response to lenvatinib monotherapy for unresectable HCC.

Usage metrics

    Clinical Cancer Research





    Ref. manager